Stocklytics Platform
Asset logo for symbol RNLX
Renalytix AI plc
RNLX
46
$0.37arrow_drop_down19.03%-$0.08
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$0.43
Prev. Close$0.45
EPS-0.76
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap34902648.00
PE Ratio-
LOWHIGH
Day Range0.38
0.43
52 Week Range0.24
4.03
Ratios
P/B Ratio20.68
Revenue$3.40M
Operating M. %-1,146.92%
Earnings$0.00
Earnings Growth %6.87%
EBITDA Margin %-971.79%
ROE %-1,073.18%
EPS-0.76

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$903.48
Perf. (24h)
arrow_drop_up1.50%$13.38
Market Cap$840.04B
Price$485.06
Perf. (24h)
arrow_drop_down1.00%-$4.92
Market Cap$451.00B
Price$147.56
Perf. (24h)
arrow_drop_down1.04%-$1.56
Market Cap$357.99B
Price$133.16
Perf. (24h)
arrow_drop_up0.15%$0.20
Market Cap$331.08B

About Renalytix AI plc (RNLX)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Health Information Services
CEO
Mr. James R. McCullough M.B.A.
Headquarters
New York
Employees
102
Exchange
NASDAQ
add Renalytix AI plc to watchlist

Keep an eye on Renalytix AI plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Renalytix AI plc (RNLX)?

For Renalytix AI plc (RNLX), the 52-week high is $4.04, which is 991.35% from the current price. The 52-week low is $0.24, the current price is 51.02% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Renalytix AI plc (RNLX) a growth stock?

Renalytix AI plc (RNLX) has shown an average price growth of 0.41% over the past three years. It has received a score of -2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Renalytix AI plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Renalytix AI plc's (RNLX) price per share?

The current price per share for Renalytix AI plc (RNLX) is $0.37. The stock has seen a price change of -$0.09 recently, indicating a -19.04% change. This reflects the stock's recent market performance and investor sentiment.

help
What is Renalytix AI plc (RNLX) stock price performance year to date (YTD)?

As of the latest data, Renalytix AI plc (RNLX) has a year-to-date price change of -12.94%. Over the past month, the stock has experienced a price change of -13%. Over the last three months, the change has been -59.19%. Over the past six months, the figure is -29.92%.

help
Is Renalytix AI plc (RNLX) a profitable company?

Renalytix AI plc (RNLX) has a net income of -$46.22M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 20.6% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.15K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.4M, with a revenue growth rate of 14.58%, providing insight into the company's sales performance and growth. The gross profit is $701K. Operating income is noted at -$42.36M. Furthermore, the EBITDA is -$33.07M.

help
What is the market capitalization of Renalytix AI plc (RNLX)?

Renalytix AI plc (RNLX) has a market capitalization of $34.9M. The average daily trading volume is 338.41K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level